Literature DB >> 11129311

Ethics of early prevention in schizophrenia.

A Rosen1.   

Abstract

OBJECTIVE: To represent a cross-section of current thinking on the ethics of early (primary) prevention in schizophrenia.
METHOD: Ethical considerations presented at the First Australian Schizophrenia Prevention Conference, Sydney, March 1999, particularly from the final session on 'Ethics', are recorded here together with complementary referenced material.
RESULTS: Ethical concerns arise in the arenas of research over clinical priorities; screening ethics, including stigma, confidentiality, informed consent and support required through waiting periods; and the ethics of prolonged assessments in the absence of disorder, the right not to know and the possible ethical prematurity or otherwise of screening for schizophrenia.
CONCLUSIONS: There are several legitimate ethical concerns that must be understood and addressed by those undertaking the developing of primary preventive measures in schizophrenia. Such measures must still be regarded as more experimental the further ahead the measures are undertaken from the onset of the disorder. Anticipatory ethical guidelines should be developed to inform such research.

Entities:  

Keywords:  Health Care and Public Health; Mental Health Therapies

Mesh:

Year:  2000        PMID: 11129311     DOI: 10.1080/000486700247

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  3 in total

Review 1.  Early intervention for psychosis.

Authors:  Max Marshall; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

2.  Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.

Authors:  Yael Piontkewitz; Michal Arad; Ina Weiner
Journal:  Schizophr Bull       Date:  2010-05-03       Impact factor: 9.306

3.  Self-report of attenuated psychotic experiences in a college population.

Authors:  Rachel L Loewy; Jennifer K Johnson; Tyrone D Cannon
Journal:  Schizophr Res       Date:  2007-04-24       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.